Effect of ibuprofen for hemodynamically significant patent ductus arteriosus closure on the development of acute kidney injury in preterm infants
Keywords:preterm infants, patent ductus arteriosus, ibuprofen, acute kidney injury
Premature infants with hemodynamically significant patent ductus arteriosus (HSPDA) have a high risk of developing acute kidney injury (AKI) due to renal hypoperfusion and use of ibuprofen for duct closure. The aim of the study was to evaluate the effect of ibuprofen for the closure of HSPDA on the development of AKI in preterm infants depending on high dose of the drug on the first day of life. 40 preterm infants with HSPDA who were admitted for observation on the first day of life were examined. To close the ductus arteriosus, infants received restrictive therapy. In addition, 32 (80,0%) preterm infants on the first day of life were prescribed ibuprofen: 19 infants – in high dose (20 mg/kg), 13 infants – in standard dose (10 mg/kg). Clinical examination and treatment of preterm infants was carried out according to the generally accepted methods. Echocardiography with Doppler was performed at 5-11 hours of life and then daily to determine the size and hemodynamic significance of patent ductus arteriosus. Diagnosis and stratification of the severity of AKI were performed according to the criteria of neonatal modification of KDIGO, for which the concentration of serum creatinine and diuresis were studied. According to the results of the study, it was established that the frequency of AKI on the third and fifth days of life in preterm infants with HSPDA, who received ibuprofen in a high dose (20 mg/kg) on the first day, was 73.7% and 84.2%, respectively, which is 2.2 (OR=5.6; CI: 1,43-21,95; р<0.02) and 2.5 (OR=10.67; CI: 2.31-49.31; р<0.002) times, more often than in infants without such therapy. High dose of ibuprofen on the first day of life in preterm infants with HSPDA are most often associated with the development of stage I AKI on the third or fifth day of life, which was temporary in one third of patients. The use of a high-dose ibuprofen for HSPDA closure on the first day of life in preterm infants was significantly more often associated with foci of infection in the mother, large duct size and furosemide use.
Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005 Apr;30(2):121-32. doi: https://doi.org/10.1111/j.1365-2710.2005.00630.x
Girardi A, Raschi E, Galletti S, Poluzzi E, Faldella G, Allegaert K, De Ponti F. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf. 2015;38(6):535-51. doi: https://doi.org/10.1007/s40264-015-0288-6
Demir N, Peker E, Ece İ, Balahoroğlu R, Tuncer O. Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. J Matern Fetal Neonatal Med. 2017 Sep;30(17):2119-25. doi: https://doi.org/10.1080/14767058.2016.1238897
Schildcrout JS, Schisterman EF, Mercaldo ND, Rathouz PJ, Heagerty PJ. Extending the Case-Control Design to Longitudinal Data: Stratified Sampling Based on Repeated Binary Outcomes. Epidemiology. 2018 Jan;29(1):67-75. doi: https://doi.org/10.1097/EDE.0000000000000764
Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clin Pharmacol Ther. 2012 Apr;91(4):590-6. doi: https://doi.org/10.1038/clpt.2011.284
de Klerk JCA, van Paassen N, van Beynum IM, Flint RB, Reiss IKM, Simons SHP. Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus. J Matern Fetal Neonatal Med. 2019 Sep 23:1-7. doi: https://doi.org/10.1080/14767058.2019.1667323
Majed B, Bateman DA, Uy N, Lin F. Patent ductus arteriosus is associated with acute kidney injury in the preterm infant. Pediatr Nephrol. 2019 Jun;34(6):1129-39. doi: https://doi.org/10.1007/s00467-019-4194-5
Obolonskyi A, Snisar V, Surkov D, Obolonska O, Kapustina O, Dereza K. Management of patent ductus arteriosus in preterm infants. Medicni perspektivi. 2019;24(2):33-40.
Selewski DT, Charlton JR, Jetton JG, et al. Neonatal Acute Kidney Injury. Pediatrics. 2015 Aug;136(2):e463-73. doi: https://doi.org/10.1542/peds.2014-3819
Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews 2020;2:CD003481. doi: https://doi.org/10.1002/14651858.CD003481.pub8
Muk T, Jiang PP, Stensballe A, Skovgaard K, Sangild PT, Nguyen DN. Prenatal Endotoxin Exposure Induces Fetal and Neonatal Renal Inflammation via Innate and Th1 Immune Activation in Preterm Pigs. Front Immunol. 2020;11:565484. doi: https://doi.org/10.3389/fimmu.2020.565484
Stritzke A, Thomas S, Amin H, Fusch C, Lodha A. Renal consequences of preterm birth. Mol Cell Pediatr. 2017;4(1):2.
Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? Congenit Heart Dis. 2019 Jan;14(1):21-26. doi: https://doi.org/10.1111/chd.12727
Weintraub AS, Connors J, Carey A, Blanco V, Green RS. The spectrum of onset of acute kidney injury in preterm infants less than 30 weeks gestation. J Perinatol. 2016;36:474-80. doi: https://doi.org/10.1038/jp.2015.217
How to Cite
Copyright (c) 2021 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.